Published in Gut on December 12, 2013
Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) | NCT00745004
A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut (2015) 1.55
Irritable bowel syndrome. Nat Rev Dis Prim (2016) 1.14
Bristol Stool Form Scale reliability and agreement decreases when determining Rome III stool form designations. Neurogastroenterol Motil (2015) 0.92
New and Emerging Treatment Options for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.91
Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther (2015) 0.87
Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol (2014) 0.83
Revival of 5-HT3 antagonism as treatment of IBS-D? Gut (2014) 0.83
Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS One (2017) 0.82
Update on the Management of Fecal Incontinence for the Gastroenterologist. Gastroenterol Hepatol (N Y) (2016) 0.80
Rotavirus and Serotonin Cross-Talk in Diarrhoea. PLoS One (2016) 0.79
IBS and IBD - separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol (2016) 0.79
Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol (2016) 0.78
Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea. Clin Gastroenterol Hepatol (2014) 0.78
Validation of a rapid, semiautomatic image analysis tool for measurement of gastric accommodation and emptying by magnetic resonance imaging. Am J Physiol Gastrointest Liver Physiol (2014) 0.78
Ondansetron and irritable bowel syndrome. Gut (2014) 0.78
Advances in IBS 2016: A Review of Current and Emerging Data. Gastroenterol Hepatol (N Y) (2016) 0.78
Novel therapeutic agents in neurogastroenterology: advances in the past year. Neurogastroenterol Motil (2014) 0.77
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res (2016) 0.77
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol (2016) 0.76
The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol (2015) 0.75
The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran. Adv Biomed Res (2016) 0.75
The fall and rise of 5-hydroxytryptamine receptor antagonists in irritable bowel syndrome with diarrhea. Gastroenterology (2014) 0.75
RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. Bioessays (2016) 0.75
Regulating effect of TongXie-YaoFang on colonic epithelial secretion via Cl(-) and HCO3(-) channel. World J Gastroenterol (2016) 0.75
Pharmacologic Agents for Chronic Diarrhea. Intest Res (2015) 0.75
An antiemetic for irritable bowel syndrome? J Fam Pract (2014) 0.75
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Drug Des Devel Ther (2017) 0.75
Diabetes Mellitus and the Colon. Curr Treat Options Gastroenterol (2017) 0.75
Post-Infectious Irritable Bowel Syndrome. Curr Gastroenterol Rep (2017) 0.75
Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterol J (2017) 0.75
FFA2 activation combined with ulcerogenic COX inhibition induces duodenal mucosal injury via the 5-HT pathway in rats. Am J Physiol Gastrointest Liver Physiol (2017) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med (2002) 6.10
The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther (1997) 5.78
Simplified assessment of segmental colonic transit. Gastroenterology (1987) 4.59
Postinfectious irritable bowel syndrome. Gastroenterology (2009) 3.17
Development of the Perceived Stress Questionnaire: a new tool for psychosomatic research. J Psychosom Res (1993) 2.96
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology (2002) 2.52
Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther (2004) 2.48
Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology (2003) 2.39
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol (2006) 2.14
Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology (2009) 1.97
Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol (2005) 1.93
The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology (2011) 1.88
Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat. J Physiol (2001) 1.78
Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology (2011) 1.70
An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol (1994) 1.62
Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol (2005) 1.52
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol (2008) 1.52
Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med (2004) 1.51
Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther (1997) 1.45
Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil (2003) 1.39
Predictors of patient-assessed illness severity in irritable bowel syndrome. Am J Gastroenterol (2008) 1.35
An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol (2003) 1.34
Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology (2010) 1.27
A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol (2008) 1.22
GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci (1990) 1.20
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol (2007) 1.17
Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol (2010) 1.16
A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion (2008) 1.15
A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology (1994) 1.14
Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther (1996) 1.06
Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther (2012) 1.05
Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol Suppl (2000) 1.03
Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci (2007) 1.00
Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol (2002) 0.96
Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. J Physiol (2008) 0.92
The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterol Motil (1999) 0.89